CG003301

CG003301 is an undisclosed targeted protein degrader (TPD) being developed by Cullgen for the treatment of various oncology indications. Developed using Cullgen's proprietary uSMITE™ (ubiquitin-mediated small molecule induced target elimination) platform, the drug is designed to selectively degrade a specific disease-causing protein by hijacking the body's ubiquitin-proteasome system. While the specific molecular target remains undisclosed, the program represents part of Cullgen's broader pipeline of small molecule degraders aimed at addressing high-value targets in cancer that may be difficult to inhibit with traditional small molecule inhibitors.